Founded Year

2011

Stage

Series E | Alive

Total Raised

$134.33M

Last Raised

$65M | 2 yrs ago

About AliveCor

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG.

AliveCor Headquarter Location

444 Castro Street Suite 600

Mountain View, California, 94041,

United States

855-338-8800

ESPs containing AliveCor

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Medical Devices

In medicine, wirelessly-connected devices can include small, portable exam tools, wearable ambulatory monitors, and large immobile pieces of medical equipment. Embedded sensors can collect data related to patient health as well as device use and performance.

AliveCor named as Leader among 9 other companies, including Babyscripts, Glooko, and TytoCare.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Biopharmaceuticals

These companies enable the capture and transmission of patient data outside of a healthcare setting. Solutions in this market include devices and/or patient engagement software that can be tailored to the specific clinical trial.

AliveCor named as Leader among 6 other companies, including Huma, BioIntelliSense, and Current Health.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AliveCor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AliveCor is included in 12 Expert Collections, including Digital Health.

D

Digital Health

12,922 items

Startups recreating how healthcare is delivered

C

Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

T

Tech IPO Pipeline

286 items

A

Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

V

Value-Based Care & Population Health

866 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

11,610 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

AliveCor Patents

AliveCor has filed 62 patents.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiac electrophysiology
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/8/2018

3/22/2022

Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Heart diseases, Cardiac procedures

Grant

Application Date

6/8/2018

Grant Date

3/22/2022

Title

Related Topics

Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Heart diseases, Cardiac procedures

Status

Grant

Latest AliveCor News

05:30 EDT Insights on the Digital Biomarkers Global Market to 2028 - Featuring AliveCor, Pear Therapeutics and Abbott Among Othe...

May 20, 2022

News provided by Share this article Share this article The global digital biomarkers market report highlights that the market was valued at $1,808.3 million in 2021 and is expected to reach $16,174.0 million by 2028. The market is expected to grow at a CAGR of 36.06% during the forecast period 2022-2028. Global Digital Biomarkers Market Drivers Conventional chronic disease diagnostics are very subjective and based on a series of visits. As a result, drug development decisions are based on limited, subjective evidence, resulting in large-scale Phase 3 trials of medications that were unsuccessful. Digital biomarkers can predict the efficacy of a drug more swiftly than a conventional clinical endpoint, thereby accelerating product development in the case of certain therapeutic areas. Moreover, the advancements in digital biomarker technology such as voice-based digital biomarkers, mHealth applications, and the adoption of smart wearable devices are gaining popularity among people. Furthermore, with the rise in prevalence and incidence of chronic diseases, technological adoption will also increase. As a result, disease diagnosis will become more prevalent, and the global market for digital biomarkers will expand. Governments invest a significant amount of money in healthcare insurance so that the overall healthcare costs can be reduced, and the quality of life and affordability of the treatment can be enhanced. Global Digital Biomarkers Market Restraints The factors restraining the growth of the global digital biomarkers devices market include the risks associated with return on investment (RoI) and the lack of standardized and interoperability solutions. Moreover, people are specifically concerned about the increased risk of medical errors and invasion of patients' privacy when digital health devices are being used instead of conventional methods. Global Digital Biomarkers Market Opportunities High growth opportunities in emerging economies and the emergence of local companies in Asia-Pacific and the Middle East and Africa hold immense potential for digital biomarkers market growth. In an era of machine learning (ML) and artificial intelligence (AI), extracting quantitative digital biomarkers that help in illness detection, characterization, monitoring, and therapy response assessment is becoming increasingly desirable. Impact of COVID-19 on the Global Digital Biomarkers Market The COVID-19 pandemic had a debilitating impact on the global healthcare ecosystem. Hospitals and clinics faced several challenges, such as lack of resources, high patient influx, and risk of infection among care providers. The market is projected to witness considerable growth during the forecast period 2022-2028. The increasing innovations and product designs in the global market and the growing use in emerging economies are the driving factors for the market's growth. Market Segmentation Global Digital Biomarkers Market (by System Components) The global digital biomarkers market based on system components product type has been segmented into data collection tools and data integration software. Data collection tools have been further segmented into wearables, implantables, and mobile applications. Global Digital Biomarkers Market (by Type) The global digital biomarkers market based on product type has been segmented into clinical trials and clinical settings. Global Digital Biomarkers Market (by Application) The global digital biomarkers market, based on application, has been segmented into gastrointestinal diseases, sleep and movement disorders, cardiovascular, psychiatric disorders (mood and behavior), neurodegenerative diseases, diabetes, respiratory diseases, and others. Global Digital Biomarkers Market (by End User) The global digital biomarkers market based on end user has been segmented into biopharmaceutical companies, providers, and payers. Global Digital Biomarkers Market (by Region) The different regions covered under the global digital biomarkers market include North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World. North America is expected to be the most lucrative region for the global digital biomarkers market due to advanced healthcare infrastructure and a high focus on research and development activities. The Asia-Pacific digital biomarkers market is one of the profitable markets with immense potential for expansion by key players in the global digital biomarkers market. The Asia-Pacific digital biomarkers market is expected to grow at the fastest rate during the forecast period. This can be attributed to the massive geriatric population base, which is driving the increase in the volume of digital biomarkers. Key Market Players and Competition Synopsis Some key players operating in the market include AliveCor, Inc., Pear Therapeutics Inc., Abbott, Akili Interactive Labs, Inc., Koninklijke Phillips N.V., Huma, Koneksa Health, Alphabet Inc., and Neurotrack Technologies, Inc. Some strategies covered in this segment are funding activities, mergers and acquisitions, partnerships, alliances, business expansions, regulatory and legal activities, and new offerings and upgradations. Key Questions Answered in the Report How has COVID-19 impacted the growth of the global digital biomarkers market? What are the key regulations governing the digital biomarkers market in key regions? What technological developments are projected to have the maximum influence on the global digital biomarkers market? Who are the leading players holding significant dominance in the global digital biomarkers market? What are some of the growth opportunities which market players can capitalize on? What are the drivers and restraints for the global digital biomarkers market? Which region has the highest growth rate in the digital biomarkers market? Which are the fastest growing countries in terms of the global digital biomarkers market? What are the key strategies being adopted by market players in the global digital biomarkers market? Key Topics Covered: 1.5.2.2 Rising Employment of Vocal Digital Biomarkers 1.5.2.3 Rising Use of Wearable Devices and Increasing Smartphone Penetration 1.5.2.4 Regulatory Flexibility toward Digital Health Solutions 1.5.2.5 Failure of Drugs for Neurodegenerative Disorders 1.5.3 Business Challenges 1.5.3.2 Inaccuracy in Data Measurements 1.5.3.3 Lack of Integration and Interoperability between Medical Records and User Generated Data 1.5.3.4 Lack of Use Cases of the Return on Investment (ROI) Analysis 1.5.4 Business Opportunities 1.5.4.2 Early Detection of Neurological Disorders Using Digital Biomarkers 1.5.4.3 Increasing Awareness for General Health Management 1.5.4.4 Upsurge in Demand of Metabolic, Cardiovascular, and Gastrointestinal Healthcare 1.5.4.5 Penetration of Digital Biomarkers in Female, Maternal, Pre- and Neo-Natal Care 1.5.4.6 Rise in Usage of Digital Biomarkers to Assess Pulmonary Health 2 Global Digital Biomarker Market (by Application) 2.1 Opportunity Assessment

AliveCor Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AliveCor Rank

  • When was AliveCor founded?

    AliveCor was founded in 2011.

  • Where is AliveCor's headquarters?

    AliveCor's headquarters is located at 444 Castro Street, Mountain View.

  • What is AliveCor's latest funding round?

    AliveCor's latest funding round is Series E.

  • How much did AliveCor raise?

    AliveCor raised a total of $134.33M.

  • Who are AliveCor's competitors?

    Competitors of AliveCor include Eko, Cardiogram, Powerful Medical, Healthy.io, Coala Life and 8 more.

You May Also Like

H
Heart Care

Heart Care helps users have healthier routines and cultivates the habit of constant health monitoring. Heart Care is not a clinical tool, but a health and wellness application. The app is a simple and intuitive design, where users can easily find all the tools they need to increase health and well-being.

Happitech Logo
Happitech

Happitech develops a CE Certified heart rhythm SDK for Android & iOS. Once integrated into an application, the company's algorithms allow medical-grade vital signs monitoring directly through a smartphone.

Steth IO Logo
Steth IO

Steth IO develops medical devices that increase the accuracy of essential medical practices. The company's portfolio of products includes a smartphone stethoscope for visualizing and hearing heart sounds.

Coala Life Logo
Coala Life

Coala Life is a medical device and digital health venture that develops solutions for patient-engaged cardiac and respiratory diagnostics. The firm produces the COALA Heart Monitor which is used to remotely follow and diagnose hearts and lungs in real-time.

Digifit Logo
Digifit

Digifit offers engaging health and fitness solutions using sensors and wearable technology integrated with mobile devices and the cloud that lets users track activities anywhere, indoors or out, with a focus on heart rate training and monitoring. Digifit is an app developer bringing heart-rate monitoring to the iPhone and now features a suite of apps that track cardio, running, Spinning and cycling data from ANT+ and Bluetooth compatible sensors, all available for download from the iTunes App Store and Google Play Store. Dedicated to developing innovative applications, grounded in science and powered by technology, Digifit helps people develop healthy habits and lead healthier, happier and longer lives.

Eko Logo
Eko

Eko creates digital health solutions including AI-enabled stethoscopes, patient and provider software, and AI-powered analytics that enable doctors, nurses, researchers, and entire health systems to change care for the heart.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.